The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Open accessAbstract
Doxorubicin is an effective anticancer drug with known cardiotoxic side effects. It has been hypothesized that doxorubicin-dependent cardiotoxicity occurs through ROS production and possibly cellular iron accumulation. Here, we found that cardiotoxicity develops through the preferential accumulation of iron inside the mitochondria following doxorubicin treatment. In isolated cardiomyocytes, doxorubicin became concentrated in the mitochondria and increased both mitochondrial iron and cellular ROS levels. Overexpression of ABCB8, a mitochondrial protein that facilitates iron export, in vitro and in the hearts of transgenic mice decreased mitochondrial iron and cellular ROS and protected against doxorubicin-induced cardiomyopathy. Dexrazoxane, a drug that attenuates doxorubicin-induced cardiotoxicity, decreased mitochondrial iron levels and reversed doxorubicin-induced cardiac damage. Finally, hearts from patients with doxorubicin-induced cardiomyopathy had markedly higher mitochondrial iron levels than hearts from patients with other types of cardiomyopathies or normal cardiac function. These results suggest that the cardiotoxic effects of doxorubicin develop from mitochondrial iron accumulation and that reducing mitochondrial iron levels protects against doxorubicin-induced cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90088-j · Cited by 517
Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3879 · Cited by 493
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles
Mayer, L. D., Hope, M. J., Cullis, P. R., & Janoff, A. S. (1985) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(85)90084-7 · Cited by 436
Adriamycin-induced oxidative mitochondrial cardiotoxicity
Berthiaume, J. M., & Wallace, K. B. (2007) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0140-y · Cited by 409
ABC proteins : from bacteria to man
Holland, I. B., Cole, S. P. C., Kuchler, K., & Higgins, C. F. (2003) · Medical Entomology and Zoology · Cited by 361
Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex
Myers, C. E., Gianni, L., Simone, C. B., Klecker, R., & Greene, R. (1982) · Biochemistry · doi:10.1021/bi00537a001 · Cited by 239
Salzer, W. L., Devidas, M., Carroll, W. L., Winick, N., Pullen, J., Hunger, S. P., & Camitta, B. A. (2010) · Leukemia · doi:10.1038/leu.2009.261 · Cited by 235
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Xu, X., Persson, H. L., & Richardson, D. R. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013383 · Cited by 235
Catalytic inhibitors of DNA topoisomerase II
Andoh, T., & Ishida, R. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00133-x · Cited by 231
Minotti, G., Ronchi, R., Salvatorelli, E., Menna, P., & Cairo, G. (2001) · PubMed · Cited by 227
Gordon, L. I., Burke, M. A., Singh, A. T. K., Prachand, S., Lieberman, E. D., Sun, L., Naik, T. J., Prasad, S. V. N., & Ardehali, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804570200 · Cited by 185
Self-citationThe role of iron in doxorubicin-induced cardiomyopathy.
Myers, C. (1998) · PubMed · Cited by 168
Miranda, C. J., Makui, H., Soares, R. J., Bilodeau, M., Mui, J., Vali, H., Bertrand, R., Andrews, N. C., & Santos, M. M. (2003) · Blood · doi:10.1182/blood-2003-03-0869 · Cited by 168
Ichikawa, Y., Bayeva, M., Ghanefar, M., Potini, V., Sun, L., Mutharasan, R. K., Wu, R., Khechaduri, A., Jairaj Naik, T., & Ardehali, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119338109 · Cited by 163
Self-citationSwain, S. M., & Vici, P. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0498-7 · Cited by 155
THE AMERICAN SOCIETY OF HEMATOLOGY
Alexander, W. (2009) · Blood · doi:10.1182/blood.v114.22.r23.r23 · Cited by 147
Petrat, F., Weisheit, D., LENSEN, M., de GROOT, H., Sustmann, R., & Rauen, U. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3620137 · Cited by 143
Jones, R. L., Swanton, C., & Ewer, M. S. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.6.791 · Cited by 132
Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes
Sarvazyan, N. A. (1996) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1996.271.5.h2079 · Cited by 127
Potentiation of Doxorubicin Cardiotoxicity by Iron Loading in a Rodent Model
Panjrath, G. S., Patel, V., Valdiviezo, C., Narula, N., Narula, J., & Jain, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.060 · Cited by 126
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Hasinoff, B. B., & Herman, E. H. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0023-3 · Cited by 123
Rauen, U., Springer, A., Weisheit, D., Petrat, F., Korth, H., de Groot, H., & Sustmann, R. (2007) · ChemBioChem · doi:10.1002/cbic.200600311 · Cited by 121
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin
Hasinoff, B. B., Patel, D., & Wu, X. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.08.005 · Cited by 115
Tangerås, A., Flatmark, T., Bäckström, D., & Ehrenberg, A. (1980) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(80)90035-3 · Cited by 105
Hasinoff, B. B., Schnabl, K. L., Marusak, R. A., Patel, D., & Huebner, E. (2003) · Cardiovascular Toxicology · doi:10.1385/ct:3:2:89 · Cited by 91
Martin, E., Thougaard, A., Grauslund, M., Jensen, P. B., Björkling, F., Hasinoff, B. B., Tjørnelund, J., Sehested, M., & Jensen, L. H. (2008) · Toxicology · doi:10.1016/j.tox.2008.10.011 · Cited by 91
Chelation and Mobilization of Cellular Iron by Different Classes of Chelators
Zanninelli, G., Glickstein, H., Breuer, W., Milgram, P., Brissot, P., Hider, R. C., Konijn, A. M., Libman, J., Shanzer, A., & Cabantchik, Z. I. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.5.842 · Cited by 83
Kwok, J., & Richardson, D. R. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.849 · Cited by 82
Clementi, M. E., Giardina, B., Stasio, E. D., Mordente, A., & Misiti, F. (2003) · PubMed · Cited by 75
Hershko, C., Link, G., Tzahor, M., Kaltwasser, J. P., Athias, P., Grynberg, A., & Pinson, A. (1993) · PubMed · Cited by 74
Update on Iron Chelators in Thalassemia
Neufeld, E. J. (2010) · Hematology · doi:10.1182/asheducation-2010.1.451 · Cited by 73
Marechal, X., Montaigne, D., Marciniak, C., Marchetti, P., Hassoun, S. M., Beauvillain, J. C., Lancel, S., & Nevière, R. (2011) · Clinical Science · doi:10.1042/cs20110069 · Cited by 69
Pathogenesis and prevention of doxorubicin cardiomyopathy.
Ferrans, V. J., Clark, J., Zhang, J., Yu, Z., & Herman, E. (1997) · PubMed · Cited by 68
Kwok, J. C., & Richardson, D. R. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.4.888 · Cited by 67
Hoyes, K. P., & Porter, J. B. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb03184.x · Cited by 62
Xu, X., Šuťák, R., & Richardson, D. R. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.041335 · Cited by 60
Hasinoff, B. B., Abram, M. E., Barnabé, N., Khélifa, T., Allan, W. P., & Yalowich, J. C. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12235-3 · Cited by 59
Herman, E., Zhang, J., & Ferrans, V. J. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686629 · Cited by 56
Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo
Popelová, O., Štěrba, M., Šimůnek, T., Mazurová, Y., Němečková, I., Hroch, M., Adamcová, M., & Geršl, V. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137604 · Cited by 56
Elihu, N., Anandasbapathy, S., & Frishman, W. H. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04397.x · Cited by 52
Synthesis and Solution Properties of Deferoxamine Amides
Ihnat, P. M., Vennerstrom, J. L., & Robinson, D. H. (2000) · Journal of Pharmaceutical Sciences · Cited by 49
Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Transcriptional regulation of myotube fate specification and intrafusal muscle fiber morphogenesis
Albert, Y. B., Whitehead, J. L., Eldredge, L. C., Carter, J., Gao, X. M., & Tourtellotte, W. G. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200501156 · Cited by 35
Herman, E. H., & Ferrans, V. J. (1990) · Cancer Treatment Reviews · doi:10.1016/0305-7372(90)90040-m · Cited by 21
Targeting of the mitochondrial membrane proteins to the cell surface for functional studies
Ardehali, H., Xue, T., Dong, P., & Machamer, C. E. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.070 · Cited by 12
Self-citation
Cited by
Ferroptosis as a target for protection against cardiomyopathy
Fang, X., Wang, H., Han, D., Xie, E., Yang, X., Wei, J., Gu, S., Gao, F., Zhu, N., Yin, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821022116 · Cited by 2,127
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease
Fang, X., Ardehali, H., Min, J., & Wang, F. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00735-4 · Cited by 1,081
Self-citationAnthracycline Chemotherapy and Cardiotoxicity
McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6711-0 · Cited by 956
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies
Zhou, Q., Meng, Y., Li, D., Yao, L., Le, J., Liu, Y., Sun, Y., Zeng, F., Chen, X., & Deng, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01769-5 · Cited by 890
Metadata
- Authors
- Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S. V. N., Mutharasan, R. K., Naik, T. J., & Ardehali, H.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-02
- Volume
- 124
- Issue
- 2
- Pages
- 617-630
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2112885253
- Cited by
- 878
- References
- 50
- FWCI
- 35.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.